Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 3, 2013, Pages 441-450

  Zhao, Xiao Qin ^a   Dai, Chun Ling ^a,b   Ohnuma, Shinobu ^c   Liang, Yong Ju ^a   Deng, Wen ^b   Chen, Jun Jiang ^b   Zeng, Mu Sheng ^a   Ambudkar, Suresh V ^c   Chen, Zhe Sheng ^b   Fu, Li Wu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b ST JOHN'S UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABCG2 BCRP; Multidrug resistance; Stem like cells; Tandutinib; Tyrosine kinase inhibitor

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; MITOXANTRONE; RHODAMINE 123; TANDUTINIB;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SENSITIZATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MITOXANTRONE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; NIH 3T3 CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RHODAMINE 123;

EID: 84878119609     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.04.015     Document Type: Article

References (57)

1. S.V. Ambudkar Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells Methods Enzymol. 292 1998 504 514
2. M. Barancik, V. Bohacova, J. Kvackajova, S. Hudecova, O. Krizanova, and A. Breier SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance Eur. J. Pharm. Sci.: Official J. Eur. Federat. Pharm. Sci. 14 2001 29 36
3. A.M. Bleau, D. Hambardzumyan, T. Ozawa, E.I. Fomchenko, J.T. Huse, C.W. Brennan, and E.C. Holland PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells Cell Stem Cell 4 2009 226 235
4. S.P. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M. Duncan, and R.G. Deeley Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
5. C.L. Dai, Y.J. Liang, L.M. Chen, X. Zhang, W.J. Deng, X.D. Su, Z. Shi, C.P. Wu, C.R. Ashby Jr., S. Akiyama, S.V. Ambudkar, Z.S. Chen, and L.W. Fu Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function Biochem. Pharmacol. 78 2009 355 364
6. C.L. Dai, Y.J. Liang, Y.S. Wang, A.K. Tiwari, Y.Y. Yan, F. Wang, Z.S. Chen, X.Z. Tong, and L.W. Fu Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2 Cancer Lett. 279 2009 74 83
7. C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, D.G. Liu, C.R. Ashby Jr., Y. Huang, R.W. Robey, Y.J. Liang, L.M. Chen, C.J. Shi, S.V. Ambudkar, Z.S. Chen, and L.W. Fu Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res. 68 2008 7905 7914
8. A.H. Dantzig, R.L. Shepard, J. Cao, K.L. Law, W.J. Ehlhardt, T.M. Baughman, T.F. Bumol, and J.J. Starling Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979 Cancer Res. 56 1996 4171 4179
9. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat. Rev. Cancer 5 2005 275 284
10. M. Dean, A. Rzhetsky, and R. Allikmets The human ATP-binding cassette (ABC) transporter superfamily Genome Res. 11 2001 1156 1166
11. C.A. Doige, X. Yu, and F.J. Sharom ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells Biochim. Biophys. Acta 1109 1992 149 160
12. C. Erlichman, S.A. Boerner, C.G. Hallgren, R. Spieker, X.Y. Wang, C.D. James, G.L. Scheffer, M. Maliepaard, D.D. Ross, K.C. Bible, and S.H. Kaufmann The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux Cancer res 61 2001 739 748
13. M.J. Flens, G.J. Zaman, P. van der Valk, M.A. Izquierdo, A.B. Schroeijers, G.L. Scheffer, P. van der Groep, M. de Haas, C.J. Meijer, and R.J. Scheper Tissue distribution of the multidrug resistance protein Am. J. Pathol. 148 1996 1237 1247
14. M.F. Fromm Importance of P-glycoprotein at blood-tissue barriers Trends Pharmacol. Sci. 25 2004 423 429
15. L. Fu, Y. Liang, L. Deng, Y. Ding, L. Chen, Y. Ye, X. Yang, and Q. Pan Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance Cancer Chemother Pharmacol. 53 2004 349 356
16. V. Gagnon, C. Van Themsche, S. Turner, V. Leblanc, and E. Asselin Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol Apoptosis 13 2008 259 271
17. M.A. Goodell, K. Brose, G. Paradis, A.S. Conner, and R.C. Mulligan Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo J. Exp. Med. 183 1996 1797 1806
18. D. Hambardzumyan, O.J. Becher, and E.C. Holland Cancer stem cells and survival pathways Cell Cycle 7 2008 1371 1378
19. T. Hegedus, L. Orfi, A. Seprodi, A. Varadi, B. Sarkadi, and G. Keri Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1 Biochim. Biophys. Acta 1587 2002 318 325
20. C. Hirschmann-Jax, A.E. Foster, G.G. Wulf, J.G. Nuchtern, T.W. Jax, U. Gobel, M.A. Goodell, and M.K. Brenner A distinct "side population" of cells with high drug efflux capacity in human tumor cells Proc. Natl. Acad. Sci. USA 101 2004 14228 14233
21. M.M. Ho, A.V. Ng, S. Lam, and J.Y. Hung Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells Cancer Res. 67 2007 4827 4833
22. P.J. Houghton, G.S. Germain, F.C. Harwood, J.D. Schuetz, C.F. Stewart, E. Buchdunger, and P. Traxler Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro Cancer Res. 64 2004 2333 2337
23. L. Hunakova, J. Sedlak, M. Sulikova, J. Chovancova, J. Duraj, and B. Chorvath Human multidrug-resistant (MRP, p190) myeloid leukemia HL-60/ADR cells in vitro: resistance to the mevalonate pathway inhibitor lovastatin Neoplasma 44 1997 366 369
24. W.J. Jansen, H.M. Pinedo, C.M. Kuiper, C. Lincke, U. Bamberger, A. Heckel, and E. Boven Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole Ann. Oncol.: Official J. Eur. Soc. Med. Oncol./ESMO 5 1994 733 739
25. T. Kessler, F. Fehrmann, R. Bieker, W.E. Berdel, and R.M. Mesters Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies Curr. Drug Targets 8 2007 257 268
26. T. Kitazaki, M. Oka, Y. Nakamura, J. Tsurutani, S. Doi, M. Yasunaga, M. Takemura, H. Yabuuchi, H. Soda, and S. Kohno Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells Lung Cancer 49 2005 337 343
27. I. Klein, B. Sarkadi, and A. Varadi An inventory of the human ABC proteins Biochim. Biophys. Acta 1461 1999 237 262
28. K. Lee, A.J. Klein-Szanto, and G.D. Kruh Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells J. Natl. Cancer Inst. 92 2000 1934 1940
29. M. Leggas, J.C. Panetta, Y. Zhuang, J.D. Schuetz, B. Johnston, F. Bai, B. Sorrentino, S. Zhou, P.J. Houghton, and C.F. Stewart Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo Cancer Res. 66 2006 4802 4807
30. T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, D.D. Ross, K. Miyake, J.H. Resau, and S.E. Bates The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) J. Cell Sci. 113 Pt 11 2000 2011 2021
31. Y.J. Mi, Y.J. Liang, H.B. Huang, H.Y. Zhao, C.P. Wu, F. Wang, L.Y. Tao, C.Z. Zhang, C.L. Dai, A.K. Tiwari, X.X. Ma, K.K. To, S.V. Ambudkar, Z.S. Chen, and L.W. Fu Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters Cancer Res. 70 2010 7981 7991
32. Y. Nakamura, M. Oka, H. Soda, K. Shiozawa, M. Yoshikawa, A. Itoh, Y. Ikegami, J. Tsurutani, K. Nakatomi, T. Kitazaki, S. Doi, H. Yoshida, and S. Kohno Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance Cancer Res. 65 2005 1541 1546
33. P.M. Navolanic, L.S. Steelman, and J.A. McCubrey EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review) Int. J. Oncol. 22 2003 237 252
34. J.E. Oates, B.R. Grey, S.K. Addla, J.D. Samuel, C.A. Hart, V.A. Ramani, M.D. Brown, and N.W. Clarke Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers Stem Cells Develop. 18 2009 1515 1522
35. S.Y. Oh, J.H. Song, J.E. Gil, J.H. Kim, Y.I. Yeom, and E.Y. Moon ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance Exp. Cell Res. 312 2006 1651 1657
36. S. Paillas, F. Boissiere, F. Bibeau, A. Denouel, C. Mollevi, A. Causse, V. Denis, N. Vezzio-Vie, L. Marzi, C. Cortijo, I. Ait-Arsa, N. Askari, P. Pourquier, P. Martineau, M. Del Rio, and C. Gongora Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma Cancer Res. 71 2011 1041 1049
37. L. Patrawala, T. Calhoun, R. Schneider-Broussard, J. Zhou, K. Claypool, and D.G. Tang Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic Cancer Res. 65 2005 6207 6219
38. C.R. Regenbrecht, H. Lehrach, and J. Adjaye Stemming cancer: functional genomics of cancer stem cells in solid tumors Stem cell Rev. 4 2008 319 328
39. R.W. Robey, Y. Honjo, K. Morisaki, T.A. Nadjem, S. Runge, M. Risbood, M.S. Poruchynsky, and S.E. Bates Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity Br. J. Cancer 89 2003 1971 1978
40. R.W. Robey, O. Polgar, J. Deeken, K.W. To, and S.E. Bates ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev. 26 2007 39 57
41. R. Roskoski Jr. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor Biochem. Biophys. Res. Commun. 338 2005 1307 1315
42. B. Sarkadi, C. Ozvegy-Laczka, K. Nemet, and A. Varadi ABCG2 - a transporter for all seasons FEBS Lett. 567 2004 116 120
43. C.W. Scharenberg, M.A. Harkey, and B. Torok-Storb The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors Blood 99 2002 507 512
44. Z. Shi, Y.J. Liang, Z.S. Chen, X.W. Wang, X.H. Wang, Y. Ding, L.M. Chen, X.P. Yang, and L.W. Fu Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo Cancer Biol. Ther. 5 2006 39 47
45. Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, R.W. Robey, S.E. Bates, T. Shen, C.R. Ashby Jr., L.W. Fu, S.V. Ambudkar, and Z.S. Chen Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res. 67 2007 11012 11020
46. Shi, Z., Tiwari, A.K., Shukla, S., Robey, R.W., Singh, S., Kim, I.W., Bates, S.E., Peng, X.X., Abraham, I., Ambudkar, S.V., Talele, T.T., Fu, L.W., Chen, Z.S., 2011. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res.
47. S. Shukla, R.W. Robey, S.E. Bates, and S.V. Ambudkar The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2 Biochemistry 45 2006 8940 8951
48. Shukla, S., Robey, R.W., Bates, S.E., Ambudkar, S.V., 2008. Sunitinib (Sutent(R), SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition: The Biological Fate of Chemicals.
49. K.A. West, S.S. Castillo, and P.A. Dennis Activation of the PI3K/Akt pathway and chemotherapeutic resistance Drug Resist. Updat. 5 2002 234 248
50. C. Wu, and B.A. Alman Side population cells in human cancers Cancer Lett. 268 2008 1 9
51. Y. Yan, X. Su, Y. Liang, J. Zhang, C. Shi, Y. Lu, L. Gu, and L. Fu Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage Mol. Cancer Ther. 7 2008 1688 1697
52. Yan, Y.Y., Zheng, L.S., Zhang, X., Chen, L.K., Singh, S., Wang, F., Zhang, J.Y., Liang, Y.J., Dai, C.L., Gu, L.Q., Zeng, M.S., T, T.T., Chen, Z.S., Fu, L.W., 2011. Blockade of Her2/neu Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu. Mol. Pharm.
53. J.J. Yang, M.N. Milton, S. Yu, M. Liao, N. Liu, J.T. Wu, L. Gan, S.K. Balani, F.W. Lee, S. Prakash, and C.Q. Xia P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor Drug Metab. Lett. 4 2010 201 212
54. S.Y. Yang, A. Miah, K.M. Sales, B. Fuller, A.M. Seifalian, and M. Winslet Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment Int. J. Oncol. 38 2011 1695 1702
55. X. Yuan, J. Curtin, Y. Xiong, G. Liu, S. Waschsmann-Hogiu, D.L. Farkas, K.L. Black, and J.S. Yu Isolation of cancer stem cells from adult glioblastoma multiforme Oncogene 23 2004 9392 9400
56. W. Zhang, B.A. Chen, J.F. Jin, Y.J. He, and Y.Q. Niu Involvement of c-Jun N-Terminal Kinase in the Reversal of Multidrug Resistance Human Leukemia Cells in Hypoxia by 5-Bromotetrandrine 2013 Leukemia & Lymphoma
57. S. Zhou, J.J. Morris, Y. Barnes, L. Lan, J.D. Schuetz, and B.P. Sorrentino Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo Proc. Natl. Acad. Sci. USA 99 2002 12339 12344